TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials

Journal of Clinical Oncology

Volumn 22, Issue 4, 2004, Pages 577-579

  Albelda, Steven M ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENZYME; VIRUS VECTOR;

CANCER; CANCER RADIOTHERAPY; CELL SECRETION; CLINICAL TRIAL; EDITORIAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRANSGENE; METHODOLOGY; NEOPLASM; NOTE; PHASE 1 CLINICAL TRIAL;

CLINICAL TRIALS, PHASE I; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; RESEARCH DESIGN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1442307870     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.964     Document Type: Editorial

References (2)

1. Senzer N, Mani S, Rosemurgy A, et al: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 22:592-601, 2004
2. Rasmussen H, Rasmussen C, Limpicki M, et al: TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9:951-957, 2002